/ANTX

ANTX Stock - AN2 Therapeutics, Inc.

Q: What is the analyst price target for ANTX?

Analyst price target information is not currently available for ANTX.

Q: What is ANTX's market cap?

Market capitalization information is not currently available for ANTX.

Healthcare|Biotechnology|NASDAQ

$1.12-1.75%

$0.02 (-1.75%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+78.6%upside

Target: $2.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for ANTX

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-0.03

52W High$1.55

52W Low$1.01

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	$-77,000	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-54,554,000	$-69,635,000	$-42,262,000	$-21,574,000	$-7,284,000
Net Income	$-51,321,000	$-64,732,000	$-40,956,000	$-21,543,000	$-13,603,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-1.72	$-2.74	$-2.79	$-1.50	$-0.78

Company Overview

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

86%

Hold / Neutral

Sell / Underperform

14%

Analyst Consensus🟢 Bullish

6 Bullish1 Neutral/Bearish

Price Targets

$13

Average Target

↑ 1016.1% Upside

Now

Low

$13

Average

$30

High

Based on 8 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
August 9th 2024	Evercore ISI	Downgrade	Underperform	-
August 9th 2024	Leerink Partners	Downgrade	Market Perform	$1← $5
July 3rd 2024	Leerink Partners	Upgrade	Outperform	$5
April 2nd 2024	JMP Securities	Upgrade	Mkt Outperform	$6
February 13th 2024	Leerink Partners	Downgrade	Market Perform	$7← $23
February 12th 2024	Evercore ISI	Downgrade	In-line	$7← $25
February 12th 2024	Oppenheimer	Downgrade	Perform	-
February 12th 2024	JMP Securities	Downgrade	Market Perform	-
January 4th 2024	JMP Securities	Initiation	Mkt Outperform	$30
July 18th 2022	Oppenheimer	Resumed	Outperform	$22
April 19th 2022	Oppenheimer	Initiation	Outperform	$22
April 19th 2022	Cowen	Initiation	Outperform	-

Earnings History & Surprises

ANTX

Beat Rate

40%

Last 15 quarters

Avg Surprise

-33.6%

EPS vs Estimate

Beats / Misses

6/7

2 met exactly

Latest EPS

$-0.31

Q4 2025

EPS Surprise History

Q1 24

+19.7%

$-0.57vs$-0.71

Q2 24

+8.2%

$-0.56vs$-0.61

Q3 24

+23.8%

$-0.48vs$-0.63

Q4 24

-16.2%

$-0.43vs$-0.37

Q1 25

0.0%

$-0.25vs$-0.25

Q2 25

-34.6%

$-0.35vs$-0.26

Q3 25

+32.3%

$-0.21vs$-0.31

Q4 25

-34.8%

$-0.31vs$-0.23

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Mar 24, 2026	$-0.24	—	—	—
Q4 2025	Nov 12, 2025	$-0.23	$-0.31	-34.8%	✗ MISS
Q3 2025	Aug 12, 2025	$-0.31	$-0.21	+32.3%	✓ BEAT
Q2 2025	May 13, 2025	$-0.26	$-0.35	-34.6%	✗ MISS
Q1 2025	Mar 25, 2025	$-0.25	$-0.25	0.0%	= MET
Q4 2024	Nov 13, 2024	$-0.37	$-0.43	-16.2%	✗ MISS
Q3 2024	Aug 13, 2024	$-0.63	$-0.48	+23.8%	✓ BEAT
Q2 2024	May 14, 2024	$-0.61	$-0.56	+8.2%	✓ BEAT
Q1 2024	Mar 28, 2024	$-0.71	$-0.57	+19.7%	✓ BEAT
Q4 2023	Nov 9, 2023	$-0.63	$-0.65	-3.2%	✗ MISS
Q3 2023	Aug 10, 2023	$-0.85	$-0.81	+4.7%	✓ BEAT
Q2 2023	May 11, 2023	$-0.68	$-0.79	-16.2%	✗ MISS
Q1 2023	Mar 29, 2023	$-0.63	$-0.61	+3.2%	✓ BEAT
Q4 2022	Nov 9, 2022	$-0.59	$-0.59	0.0%	= MET
Q3 2022	Aug 11, 2022	$-0.45	$-0.53	-17.8%	✗ MISS
Q2 2022	May 10, 2022	$-0.52	$-2.98	-473.1%	✗ MISS
Q1 2022	Mar 28, 2022	—	$-0.49	—	—
Q4 2021	Dec 31, 2021	—	$-0.42	—	—
Q2 2021	Jun 30, 2021	—	$-0.36	—	—
Q1 2021	Mar 31, 2021	—	$-0.15	—	—

Frequently Asked Questions about ANTX

What is ANTX's current stock price?

AN2 Therapeutics, Inc. (ANTX) is currently trading at $1.12 per share. The stock has moved -1.75% today.

What is the analyst price target for ANTX?

The average analyst price target for ANTX is $2.00, based on 1 analyst.

What sector is AN2 Therapeutics, Inc. in?

AN2 Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is ANTX's market cap?

AN2 Therapeutics, Inc. has a market capitalization of $0.03 billion, making it a small-cap company.

Does ANTX pay dividends?

No, AN2 Therapeutics, Inc. does not currently pay a dividend to shareholders.